STOCKSA Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?By Adam FeuersteinMay 3, 2017 2:58 PM EDT
PRESS RELEASESNeurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis For Advanced Alzheimer's Disease TrialBy PR NewswireJan 22, 2020 9:00 AM EST
STOCKSA Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?By Adam FeuersteinMay 3, 2017 2:58 PM EDT
FUTURESTech Leads Nasdaq to New Records, Congress Deal Boosts S&P 500By Keris Alison LahiffMay 1, 2017 4:17 PM EDT
FUTURESStocks Move Higher, Nasdaq at Records as Congress Makes Funding DealBy Keris Alison LahiffMay 1, 2017 11:09 AM EDT
FUTURESStock Futures Climb After Congress Reaches Funding Deal to Avoid Government ShutdownBy Keris Alison LahiffMay 1, 2017 8:39 AM EDT
STOCKSBiotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's RiskBy Adam FeuersteinMar 24, 2017 8:34 AM EDT
STOCKSNeurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call NearsBy Adam FeuersteinMar 13, 2017 12:51 PM EDT
